NYSE:DVA DaVita (DVA) Stock Price, News & Analysis $151.47 +5.42 (+3.71%) Closing price 07/23/2025 03:59 PM EasternExtended Trading$149.10 -2.37 (-1.56%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DaVita Stock (NYSE:DVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DaVita alerts:Sign Up Key Stats Today's Range$146.77▼$151.8550-Day Range$134.44▼$146.7752-Week Range$131.76▼$179.60Volume1.21 million shsAverage Volume812,679 shsMarket Capitalization$11.44 billionP/E Ratio15.01Dividend YieldN/APrice Target$167.40Consensus RatingHold Company Overview DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado. Read More DaVita Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreDVA MarketRank™: DaVita scored higher than 88% of companies evaluated by MarketBeat, and ranked 123rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageDaVita has only been the subject of 1 research reports in the past 90 days.Read more about DaVita's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth18.12% Earnings GrowthEarnings for DaVita are expected to grow by 18.12% in the coming year, from $10.76 to $12.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DaVita is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.64.Price to Earnings Ratio vs. SectorThe P/E ratio of DaVita is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.08.Price to Earnings Growth RatioDaVita has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioDaVita has a P/B Ratio of 31.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DaVita's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.48% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in DaVita has recently decreased by 1.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaVita does not currently pay a dividend.Dividend GrowthDaVita does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.06 Percentage of Shares Shorted8.48% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in DaVita has recently decreased by 1.93%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment1.34 News SentimentDaVita has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for DaVita this week, compared to 12 articles on an average week.Search InterestOnly 5 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DaVita insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of DaVita is held by insiders.Percentage Held by Institutions90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DaVita's insider trading history. Receive DVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter. Email Address DVA Stock News Headlines3 Reasons to Avoid DVA and 1 Stock to Buy InsteadJuly 23 at 6:32 AM | msn.comDaVita Inc. Schedules 2nd Quarter 2025 Investor Conference CallJuly 17, 2025 | prnewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. | Porter & Company (Ad)DaVita Amends Credit Agreement with $250M LoanJuly 17, 2025 | tipranks.comDaVita’s Quarterly Earnings Preview: What You Need to KnowJuly 16, 2025 | msn.comDaVita HealthCare (DVA) Dips More Than Broader Market: What You Should KnowJuly 15, 2025 | msn.comDaVita Reveals Its Developments Towards ESG Goals in Its Community Care ReportJuly 13, 2025 | finance.yahoo.comDaVita's (NYSE:DVA) investors will be pleased with their respectable 74% return over the last three yearsJuly 11, 2025 | finance.yahoo.comSee More Headlines DVA Stock Analysis - Frequently Asked Questions How have DVA shares performed this year? DaVita's stock was trading at $149.55 at the start of the year. Since then, DVA stock has increased by 1.3% and is now trading at $151.4740. How were DaVita's earnings last quarter? DaVita Inc. (NYSE:DVA) issued its quarterly earnings results on Monday, May, 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The firm's revenue was up 5.0% compared to the same quarter last year. Read the conference call transcript. Does DaVita have any subsidiaries? The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others. Who are DaVita's major shareholders? DaVita's top institutional investors include Wedge Capital Management L L P NC (0.36%), Robeco Institutional Asset Management B.V. (0.06%), Stolper Co (0.06%) and Abacus FCF Advisors LLC (0.05%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale and Barbara J Desoer. View institutional ownership trends. How do I buy shares of DaVita? Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DaVita own? Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/12/2025Today7/23/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealth Care Services Current SymbolNYSE:DVA CIK927066 Webwww.davita.com Phone(720) 631-2100Fax302-636-5454Employees76,000Year Founded1999Price Target and Rating Average Price Target for DaVita$164.50 High Price Target$184.00 Low Price Target$145.00 Potential Upside/Downside+8.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$10.09 Trailing P/E Ratio15.01 Forward P/E Ratio14.08 P/E Growth1.01Net Income$936.34 million Net Margins6.63% Pretax Margin11.14% Return on Equity176.11% Return on Assets4.66% Debt Debt-to-Equity Ratio23.18 Current Ratio1.25 Quick Ratio1.20 Sales & Book Value Annual Sales$12.82 billion Price / Sales0.89 Cash Flow$19.85 per share Price / Cash Flow7.63 Book Value$4.83 per share Price / Book31.36Miscellaneous Outstanding Shares75,500,000Free Float73,990,000Market Cap$11.44 billion OptionableOptionable Beta1.11 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:DVA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.